Cefiderocol Combats Difficult-to-Treat Bacterial Infections

Article

Shionogi shared positive clinical cure rates from their ongoing trial of Fetroja (cefiderocol) for difficult-to-treat Gram-negative infections.

Shionogi shared positive clinical cure rates from their ongoing trial of Fetroja (cefiderocol) for difficult-to-treat Gram-negative infections.

At this year’s ID Week conference, Shionogi will present real-world data suggesting the safety and efficacy of Fetroja (cefiderocol) for difficult-to-treat, Gram-negative bacterial infections.

Today, Shionogi shared real-world trial data demonstrating a 63% clinical cure rate for patients with Acinetobacter baumannii or Pseudomonas aeruginosa infection. In early use experience, including for patients with limited treatment options, 80% of patients treated with cefiderocol cleared their difficult-to-treat Gram-negative infections.

Antimicrobial resistance is a growing public health concern, with dangerous pathogens learning to evade treatment and causing approximately 700000 deaths each year. There is a significant need for novel therapies to combat these difficult-to-treat bacteria.

Shionogi’s PROVE (Retrospective Cefiderocol Chart Review) trial is an ongoing international retrospective study of the safety and efficacy of cefiderocol in hospitalized patients with highly resistant Gram-negative bacterial infections.

The participants included 76 with Acinetobacter baumannii infections and 120 with Pseudomonas aeruginosa infections. Among these cohorts, 96% those infected with Acinetobacter baumannii were resistant to carbapenems, and 97% of those with Pseudomonas aeruginosa had carbapenem resistance.

The safety and efficacy of cefiderocol was consistent with other studies. Adverse event data was reported for 53 patients, with 24.5% reporting adverse events and 75.5% not reporting adverse events. Of all participants, 5 experienced adverse drug reactions, among whom 2 had rashes, 1 saw a severe increase in liver function test values, and 2 had diarrhea. In 2 patients, cefiderocol treatment was withdrawn.

For both the Acinetobacter baumannii and Pseudomonas aeruginosa patients, 79% were alive and 21% died within 30 days of initiating cefiderocol treatment (30-day all-cause mortality).

Previous studies found cefiderocol was the only treatment option with demonstrated activity against more than 80% of all the tested difficult-to-treat, Gram-negative pathogens.

The investigators concluded that this real-world study of cefiderocol therapy yielded high rates of clinical cure and microbiological eradication, with most patients alive after treatment. “Cefiderocol appears to be a promising therapy for patients with Gram-negative bacteria infections who have limited treatment options,” they wrote.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.